Feasibility and outcome of cognitive behavioral analysis system of psychotherapy (CBASP) for chronically depressed inpatients: a pilot study.
Eva-Lotta Brakemeier, Vera Engel, Elisabeth Schramm...
https://pubmed.ncbi.nlm.nih.gov/21389759/Actively Recruiting
Led by University of Greifswald · Updated on 2026-05-26
396
Participants Needed
8
Research Sites
87 weeks
Total Duration
Researchers are comparing two psychotherapy programs, the Cognitive Behavioral Analysis System of Psychotherapy CBASP and Behavioral Activation BA, in adults with persistent depressive disorder PDD who have not responded well to previous treatments. This study focuses on hospitalized patients with treatment-resistant depression and aims to evaluate which therapy is more effective in reducing depressive symptoms over 16 weeks. The study also explores factors that affect treatment response and the long-term effects of these therapies. Participants will receive either CBASP or BA treatment during a 10-week acute phase consisting of inpatient or dayclinic therapy followed by a 6-week outpatient continuation phase with group therapy. Both therapies include individual and group sessions, nurse contacts, and exercise therapy during inpatient treatment. All patients will also receive optimized antidepressant medication according to standard guidelines, with adjustments if needed based on response. During the study, participants will undergo regular assessments using various depression rating scales, symptom inventories, and quality of life questionnaires from baseline through 64 weeks after treatment start. Researchers will monitor responses, remission, relapse rates, and cost-effectiveness of the treatments. The total study duration includes acute treatment, continuation therapy, and long-term follow-up to evaluate sustained outcomes and health economic impacts.
CONDITIONS
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
E
Eva-Lotta Brakemeier, Prof. Dr.
J
Johannes Zimmermann, Prof. Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Greifswald
Lead Sponsor
German Research Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 10 weeks
Participants receive 10 weeks of inpatient or dayclinic treatment involving individual and group psychotherapy sessions, nurse contacts, exercise therapy, and standardized antidepressant medication.
Weekly therapy sessions and nurse contacts during inpatient/dayclinic stay
Duration - 6 weeks
Participants continue treatment with weekly outpatient group therapy sessions for 6 weeks following inpatient care.
Weekly outpatient group therapy visits
Duration - Up to 48 weeks after treatment ends
Participants are monitored to assess long-term treatment outcomes including symptom remission and relapse rates.
Periodic follow-up visits for assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Eva-Lotta Brakemeier, Vera Engel, Elisabeth Schramm...
https://pubmed.ncbi.nlm.nih.gov/21389759/David A Richards, David Ekers, Dean McMillan...
https://pubmed.ncbi.nlm.nih.gov/27461440/Kiyomi Shinohara, Mina Honyashiki, Hissei Imai...
https://pubmed.ncbi.nlm.nih.gov/24129886/Stephan Köhler, Philipp Sterzer, Claus Normann...
https://pubmed.ncbi.nlm.nih.gov/26610341/Melissa Snarski, Forrest Scogin, Elizabeth DiNapoli...
https://pubmed.ncbi.nlm.nih.gov/21292056/Sona Dimidjian, Steven D Hollon, Keith S Dobson...
https://pubmed.ncbi.nlm.nih.gov/16881773/Eva-Lotta Brakemeier, Martina Radtke, Vera Engel...
https://pubmed.ncbi.nlm.nih.gov/25547778/Anne Guhn, Stephan Köhler, Eva-Lotta Brakemeier...
https://pubmed.ncbi.nlm.nih.gov/31300878/Eva-Lotta Brakemeier, Jana Dobias, Julia Hertel...
https://pubmed.ncbi.nlm.nih.gov/29306947/Tom Bschor, Michael Bauer, Mazda Adli
https://pubmed.ncbi.nlm.nih.gov/25467053/University of Greifswald
Lead Sponsor
German Research Foundation
Collaborating Sponsor